| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Profit before tax | -2.1 | -0.9 |
| Net income | -2.1 | -0.9 |
| EPS (diluted, $ a share) | $-0.11 | $-0.06 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: GRCE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Grace Therapeutics, Inc.: key numbers
- Share price
- $1.75Close, Nov 16
- Market cap
- $36.8M
- Shares outstanding
- 21.04MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Grace Therapeutics, Inc.
All →Grace Therapeutics Financial Results
Grace Therapeutics reported financial results for the quarter ended September 30, 2026, with a net loss of $2.1 million. The company is currently focused on resubmitting its New Drug Application (NDA) for GTx-104 after addressing CMC and non-clinical items identified by the FDA. Management noted that a recent $10 million financing has extended the company's cash runway through the end of 2028.
“With no clinical safety or efficacy deficiencies identified in the U.S. Food and Drug Administration’s (FDA) Complete Response Letter (CRL), we continue to execute our plan to address the chemistry, manufacturing and controls (CMC) and non-clinical data items, and are making progress toward resubmission of our New Drug Application (NDA) for GTx-104.”
Prashant Kohli, Chief Executive Officer
“The financing concluded in August extends our expected cash runway through the end of calendar 2028, and positions us well as we work toward NDA resubmission.”
Prashant Kohli, Chief Executive Officer
Grace Therapeutics Insider Opaleye Management Inc. Buys $18.5K of Stock
Opaleye Management Inc. bought 10,328 shares of Grace Therapeutics, Inc. at $1.79 a share, worth $18.5K in total on Nov 3, 2026. Shares held after the trade: 3,046,739 (+0.3%).
- Value
- $18.5K
- Shares
- 10,328
- Price
- $1.79
- Holding change
- +0.3%
- Trade date
- Nov 3, 2026
Grace Therapeutics Insider Opaleye Management Inc. Buys $159K of Stock
Opaleye Management Inc. bought 87,801 shares of Grace Therapeutics, Inc. at $1.77 to $1.93 a share (average $1.81) in 2 transactions, worth $159K in total between Oct 22, 2026 and Oct 26, 2026. Shares held after the trade: 3,036,411 (+2.2%).
- Value
- $159K
- Shares
- 87,801
- Average price
- $1.81
- Holding change
- +2.2%
- Trade date
- Oct 22, 2026 to Oct 26, 2026
Grace Therapeutics Insider Opaleye Management Inc. Buys $136K of Stock
Opaleye Management Inc. bought 71,065 shares of Grace Therapeutics, Inc. at $1.89 to $1.95 a share (average $1.92) in 3 transactions, worth $136K in total between Oct 14, 2026 and Oct 16, 2026. Shares held after the trade: 2,944,354 (+1.2%).
- Value
- $136K
- Shares
- 71,065
- Average price
- $1.92
- Holding change
- +1.2%
- Trade date
- Oct 14, 2026 to Oct 16, 2026
Grace Therapeutics Insider Opaleye Management Inc. Buys $25.5K of Stock
Opaleye Management Inc. bought 12,555 shares of Grace Therapeutics, Inc. at $2.02 to $2.04 a share (average $2.03) in 2 transactions, worth $25.5K in total between Oct 9, 2026 and Oct 12, 2026. Shares held after the trade: 2,873,289 (+0.3%).
- Value
- $25.5K
- Shares
- 12,555
- Average price
- $2.03
- Holding change
- +0.3%
- Trade date
- Oct 9, 2026 to Oct 12, 2026
Grace Therapeutics Insider Opaleye Management Inc. Buys $120K of Stock
Opaleye Management Inc. bought 58,796 shares of Grace Therapeutics, Inc. at $2.04 to $2.07 a share (average $2.05) in 2 transactions, worth $120K in total between Oct 1, 2026 and Oct 2, 2026. Shares held after the trade: 2,856,963 (+0.7%).
- Value
- $120K
- Shares
- 58,796
- Average price
- $2.05
- Holding change
- +0.7%
- Trade date
- Oct 1, 2026 to Oct 2, 2026